Loading
A phase 1 trial of ISB 2001 in Multiple myeloma, run by Ichnos Sciences SA, now recruiting.
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) is a phase 1 interventional study registered as NCT05862012 by Ichnos Sciences SA, with 200 participants planned, started 2023-11-01 and due to reach its primary completion in 2027-07. Interventions recorded: ISB 2001, ISB 2001. Conditions recorded: Relapsed/Refractory Multiple Myeloma.
Linked to the drug ISB 2001 because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/